Franco Cecchi
YOU?
Author Swipe
View article: Development of a smartphone-based app to support the differential diagnosis in patients with primary left ventricular hypertrophy
Development of a smartphone-based app to support the differential diagnosis in patients with primary left ventricular hypertrophy Open
Aims Patients with primary left ventricular hypertrophy (LVH) often experience a diagnostic delay of several years, largely related to fragmented knowledge among different specialties and the rarity of the conditions. We developed and vali…
View article: Exploring health locus of control among vaccine-hesitant parents: a scoping review
Exploring health locus of control among vaccine-hesitant parents: a scoping review Open
Objectives This scoping review aimed to explore the relationship between health locus of control (HLOC) and vaccine hesitancy among parents of children aged 0–18 years, focusing on the tools and methods used to assess these constructs. Des…
View article: The Influence of Genotype on the Cardiopulmonary Test Response in Patients Affected by Hypertrophic Cardiomyopathy
The Influence of Genotype on the Cardiopulmonary Test Response in Patients Affected by Hypertrophic Cardiomyopathy Open
In hypertrophic cardiomyopathy (HCM), the presence of pathogenic/likely pathogenic (P/LP) disease-causing genetic variants may indicate a worse prognosis. Few data exist on the effects of these genetic variants on cardiopulmonary exercise …
View article: Cross-cultural adaptation and multicentric validation of the Italian version of the Simplified Evaluation of CONsciousness Disorders (SECONDs)
Cross-cultural adaptation and multicentric validation of the Italian version of the Simplified Evaluation of CONsciousness Disorders (SECONDs) Open
Introduction The Coma Recovery Scale-Revised (CRS-R) is the recommended tool to assess consciousness in patients with prolonged Disorders of Consciousness (pDoC). However, the time needed to administer it may limit its use. A shorter tool …
View article: Estrategias, adaptación y ruinas. El despertar del arte chino contemporáneo y la búsqueda del diálogo (1978-2018)
Estrategias, adaptación y ruinas. El despertar del arte chino contemporáneo y la búsqueda del diálogo (1978-2018) Open
Conceived in the context of a broad investigation into the history of art and terri-tory, this article draws a broad trajectory of some of the most outstanding contributions of the artistic vanguard in China starting from the era of reform…
View article: Italian Cardiological Guidelines (COCIS) for Competitive Sport Eligibility in athletes with heart disease: update 2024
Italian Cardiological Guidelines (COCIS) for Competitive Sport Eligibility in athletes with heart disease: update 2024 Open
Nearly 35 years after its initial publication in 1989, the Italian Society of Sports Cardiology and the Italian Federation of Sports Medicine (FMSI), in collaboration with other leading Italian Cardiological Scientific Associations (ANCE -…
View article: HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer Open
Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We describe an image analysis-ba…
View article: Long-term outcomes associated with subcutaneous implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy
Long-term outcomes associated with subcutaneous implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy Open
Background In patients with Hypertrophic Cardiomyopathy (HCM) S-ICD is usually the preferred option as pacing is generally not indicated. However, limited data are available on its current practice adoption and long term follow-up. Purpose…
View article: HER2 quantitative continuous scoring for accurate patient selection in HER2-negative trastuzumab deruxtecan–treated breast cancer
HER2 quantitative continuous scoring for accurate patient selection in HER2-negative trastuzumab deruxtecan–treated breast cancer Open
Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We describe an image analysis-ba…
View article: Corrigendum to ‘Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management’ [International Journal of Cardiology, 2023, 41:180–186]
Corrigendum to ‘Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management’ [International Journal of Cardiology, 2023, 41:180–186] Open
The authors regret to inform the readers that affiliations for Gianfranco Parati were not properly identified. The current format of affiliations for all authors are as below: Michele Brignole a,*, Franco Cecchi a, Aris Anastasakis b, Lia …
View article: Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator
Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator Open
Aims The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at risk of sudden cardiac death. Implantable cardioverter-defibrillator complications are of concern. The sub…
View article: Stage-specific therapy for hypertrophic cardiomyopathy
Stage-specific therapy for hypertrophic cardiomyopathy Open
Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disease and is defined by otherwise unexplained left ventricular hypertrophy. The main complications include heart failure and arrhythmias such as atrial fibrillatio…
View article: Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy Open
The standard 12-lead electrocardiogram (ECG) represents a cornerstone for the diagnosis and evaluation of hypertrophic cardiomyopathy (HCM), the most common genetically determined heart muscle disease, due to its cost-effectiveness and wid…
View article: Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy Open
Background: Although disopyramide has been widely used to reduce left ventricular outflow obstruction (LVOTO) and to improve symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM), its use in real world as well as patient…
View article: Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Supplementary Figure Legends
View article: Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
CONSORT diagram
View article: Supplementary Fig 5 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Supplementary Fig 5 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers Open
Supplementary Fig 5
View article: Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers Open
Supplementary Fig 4
View article: Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an…
View article: Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
View article: Supplementary Fig 6 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Supplementary Fig 6 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers Open
Supplementary Fig 6
View article: Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
CONSORT diagram
View article: Supplementary Tables S1-S4 from Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal Adenocarcinoma
Supplementary Tables S1-S4 from Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal Adenocarcinoma Open
Four Supplementary Tables